BioRestorative Therapies raises $1.085 million in registered offering

MELVILLE, N.Y. - BioRestorative Therapies, Inc. (NASDAQ:BRTX), a clinical-stage company with a strong liquidity position and current ratio of 2.07, announced Monday it has entered into definitive agreements to sell 678,125 shares of common stock at $1.60 per share in a registered direct offering, raising approximately $1.085 million in gross proceeds.

The offering price represents a premium to the company’s closing price of $1.50 per share on October 3, 2025. As part of the transaction, BioRestorative will also issue unregistered warrants to purchase up to 508,594 additional shares at an exercise price of $2.75 per share in a concurrent private placement. According to InvestingPro analysis, the company holds more cash than debt on its balance sheet, with impressive gross profit margins of 94.5%.

The warrants will become exercisable six months after issuance and will expire five years from the issuance date. The transaction is expected to close on or about October 8, 2025.

"We appreciate the support of this high-conviction group of existing and new healthcare specialist investors, anchored by our largest institutional shareholder," said Lance Alstodt, Chief Executive Officer of BioRestorative, according to the press release.

BioRestorative plans to use the proceeds to support clinical trials of its lead cell therapy candidate BRTX-100, advance pre-clinical research for its metabolic ThermoStem Program, develop its commercial biocosmeceuticals platform, and for general corporate purposes. With analysts forecasting sales growth of 226% for the current year, investors can access detailed growth projections and 10+ additional ProTips through InvestingPro’s comprehensive research reports.

Alere Financial Partners, a division of Cova Capital Partners, LLC, served as the exclusive placement agent for the offering.

BioRestorative is a clinical-stage company developing stem cell-based therapies primarily focused on disc/spine disease treatments and metabolic disorders. Its lead candidate, BRTX-100, is currently in Phase 2 clinical trials for chronic lower back pain arising from degenerative disc disease. The company’s stock shows a negative beta of -0.78, indicating it often moves counter to broader market trends, which could offer portfolio diversification benefits.

In other recent news, BioRestorative Therapies reported its financial results for the second quarter of 2025. The company experienced a notable 240% increase in revenue, reaching $303,000 compared to the same period last year. However, it also reported a net loss of $2.7 million, or $0.30 per share. Additionally, BioRestorative Therapies held its Annual Meeting of Stockholders where shareholders approved the election of Francisco Silva and David Rosa as Class II directors. Silva received 1,591,913 votes in favor, while Rosa garnered 1,473,937 votes. Shareholders also approved an amendment to the company’s stock plan. These developments reflect ongoing activities and changes within the company as it navigates its financial and strategic objectives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.